


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:


LISTING OF CLAIMS:

1. (Currently amended) A compound represented by the formula



wherein Ring A represents an optionally substituted pyridine ring, X represents an electron-attracting group, Y represents an optionally substituted divalent C₁₋₆ chained hydrocarbon group selected from the group consisting of a C₁₋₆ alkylene group, a C₂₋₆ alkenylene group, and a C₂₋₆ alkynylene group, R¹ represents an optionally substituted hydrocarbon group selected from the group consisting of aliphatic hydrocarbon group, alicyclic hydrocarbon group, alicyclic-aliphatic hydrocarbon group and aromatic hydrocarbon group, and R² and R³ each independently represent a hydrogen atom, an optionally substituted hydrocarbon group selected from the group consisting of aliphatic hydrocarbon group, alicyclic hydrocarbon group, alicyclic-aliphatic hydrocarbon group and aromatic hydrocarbon group or an optionally substituted heterocyclic group selected from the group consisting of a 5- to 14-membered (mono- to tri-cyclic) heterocyclic group containing 1 to 4 hetero atoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, or R² and R³ may form an optionally substituted ring together with an adjacent nitrogen atom, or a salt thereof.

2. (Original) The compound according to claim 1 which is a compound represented by the formula



wherein Ring A'' represents a pyridine ring which may have 1 to 3 substituents selected from a C₁₋₄ alkyl group and a mono-, di- or tri-halogeno-C₁₋₄ alkyl group and other symbols are as defined in claim 1, or a salt thereof.

3. (Original) The compound according to claim 1, wherein X is a nitrile group.

4. (Original) The compound according to claim 1, wherein Y is -CH=CH- or -(CH₂)₂-.

5. (Original) The compound according to claim 1, wherein R¹ is (1) a C₅₋₇ cycloalkyl group optionally fused with a benzene ring, (2) a C₇₋₁₉ aralkyl group, (3) a 5- or 6-membered heterocyclic ring-C₁₋₄ alkyl group or (4) a C₆₋₁₄ aryloxy-C₁₋₄ alkyl group, each of which may have 1 to 4 substituents selected from a halogen atom, a C₁₋₄ alkyl group, a mono-, di- or tri-halogeno-C₁₋₄ alkyl group and a C₁₋₄ alkoxy group.

6. (Original) The compound according to claim 1, wherein one of R² and R³ is a hydrogen atom or a C₁₋₄ alkyl group, and the other is a 5- or 6-membered heterocyclic group, a C₆₋₁₄ aryl group, a C₇₋₁₉ aralkyl group, a C₃₋₁₀ cycloalkyl group, a 5- or 6-membered heterocyclic ring-C₁₋₄ alkyl group or C₁₋₆ alkyl group, each of which may have 1 to 4 substituents selected from a halogen atom, a C₁₋₄ alkyl group, a mono-, di- or tri-halogeno-C₁₋₄ alkyl group, a C₁₋₄

alkoxy group, a C₁₋₄ alkoxy-carbonyl group, a cyano group, a C₁₋₄ alkyl-carbonylamino group and a hydroxy group; or R² and R³, together with an adjacent nitrogen atom, form a 5- or 6-membered nitrogen-containing heterocyclic ring optionally containing 1 to 3 hetero atoms selected from an oxygen atom, a sulfur atom and a nitrogen atom in addition to carbon atoms and one nitrogen atom, in which the nitrogen-containing heterocyclic ring may have 1 to 4 substituents selected from a halogen atom, a C₁₋₄ alkyl group, a mono-, di- or tri-halogeno-C₁₋₄ alkyl group, a C₁₋₄ alkoxy group and a C₁₋₄ alkoxy-carbonyl group.

7. (Original) (2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-(3,4-dimethoxyphenyl)prop-2-enamide,

(2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-(3,4-dimethylphenyl)prop-2-enamide,

(2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-methyl-N-phenylprop-2-enamide,

(2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-(3-methylphenyl)prop-2-enamide,

(2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-(4-hydroxy-3-methoxyphenyl)prop-2-enamide, or salts thereof.

8. (Canceled)

9. (Currently amended) A medicine comprising the compound according to claim 1 ~~or a prodrug thereof~~.

10. (Original) The medicine according to claim 9 which is a vanilloid receptor agonist.

11. (Original) The vanilloid receptor agonist according to claim 10 which is for local administration.

12. (Original) The vanilloid receptor agonist according to claim 10 which is an agent for preventing and/or treating overactive bladder.

13. (Original) The vanilloid receptor agonist according to claim 10 which is an analgesic.

14. (Currently amended) A method of ~~preventing and/or~~ treating overactive bladder, comprising administering to a mammal in need an effective amount of the compound according to claim 1 or a prodrug thereof.

15. (Currently amended) An analgesic method comprising administering to a mammal in need an effective amount of the compound according to claim 1 ~~or a prodrug thereof~~.

16. (Withdrawn) Use of the compound according to claim 1 or a prodrug thereof for manufacturing an agent for preventing and/or treating overactive bladder.

17. (Withdrawn) Use of the compound according to claim 1 or a prodrug thereof for manufacturing an analgesic.